Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)

Rhumbline Advisers grew its position in 2seventy bio, Inc. (NASDAQ:TSVT) by 9.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 84,670 shares of the company’s stock after acquiring an additional 7,379 shares during the period. Rhumbline Advisers owned 0.16% of 2seventy bio worth $249,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Geode Capital Management LLC raised its position in 2seventy bio by 1.1% in the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after purchasing an additional 13,144 shares during the last quarter. State Street Corp raised its holdings in 2seventy bio by 1.5% in the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after buying an additional 15,638 shares during the last quarter. Western Standard LLC bought a new position in 2seventy bio in the 3rd quarter valued at approximately $1,350,000. Wellington Management Group LLP boosted its position in 2seventy bio by 9.0% during the 3rd quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock worth $1,237,000 after buying an additional 21,673 shares during the period. Finally, BBR Partners LLC grew its holdings in 2seventy bio by 620.0% during the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after acquiring an additional 155,000 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

2seventy bio Price Performance

Shares of TSVT stock opened at $2.66 on Monday. The stock has a market capitalization of $137.22 million, a PE ratio of -1.43 and a beta of 1.73. The business’s 50 day simple moving average is $2.60 and its 200 day simple moving average is $3.70. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.20.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.